Patient Education Sheet Library
Search Results
Decitabine/Cedazuridine and Venetoclax
The combination of decitabine/cedazuridine and venetoclax is used for acute myeloid leukemia (AML).
Treatment Taken by MouthDownloads:
Download (English)Acalabrutinib, Venetoclax, and Obinutuzumab
The combination of acalabrutinib, venetoclax, and obinutuzumab is used for chronic lymphocytic leukemia (CLL) or…
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Acalabrutinib and Venetoclax
The combination of acalabrutinib and venetoclax is used for chronic lymphocytic leukemia (CLL) or small…
Treatment Taken by MouthDownloads:
Downloads:
Downloads:
Cladribine, Cytarabine, and Venetoclax
The combination of cladribine, cytarabine, and venetoclax is used for acute myeloid leukemia (AML).
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Ibrutinib and BR
The combination of ibrutinib and BR (bendamustine and rituximab) is used for chronic lymphocytic leukemia…
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Ibrutinib and Obinutuzumab
The combination of ibrutinib and obinutuzumab is used for chronic lymphocytic leukemia (CLL) or small…
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Downloads:
Sirolimus
Sirolimus is used for graft-versus-host disease (GVHD) and certain types of soft tissue sarcoma.
Treatment Taken by MouthDownloads:
Popular Searches
PES Review Committee
The Patient Education Sheet (PES) Committee is a multidisciplinary team of oncology professionals who guide the development and review of these important resources. This committee ensures that every PES is accurate, clear, and meaningful for patients and caregivers navigating cancer treatment.
Led by NCODA and supported through collaboration with three leading professional organizations—ACCC, HOPA, and ONS—the committee combines expertise from across the oncology care spectrum. Together, they uphold best practices, promote consistency in patient education, and remain committed to improving outcomes through accessible, patient-centered information.
